RxDoctor Payments DataLook up a doctor →

Bhaskar Palekar, MD

Internal Medicine · Lewes, DENPI 1750329322

Payments from drug & device makers

$21,735in general payments, 2019–2025

Across 758 payments — averaging $28.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • AstraZeneca$3K
  • Novo Nordisk$3K
  • Medtronic$1K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$21,58799%
  • Education$1481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)64$2,852
AstraZeneca(2 entities)74$2,564
Novo Nordisk125$2,530
Medtronic(3 entities)17$1,352
AbbVie(2 entities)48$1,218
Lilly USA, LLC51$1,124
Boehringer Ingelheim22$1,059
Daiichi Sankyo Inc.36$770
Pfizer35$591
GSK13$470
Astellas Pharma US Inc16$468
Sanofi-aventis U.S. LLC19$447
Abbott23$436
Dexcom, Inc.11$388
E.r. Squibb & Sons, L.L.C.3$365
Esperion Therapeutics, Inc.16$256
Boston Scientific3$255
Merck13$244
Amarin Pharma, Inc.15$227
Novartis8$211
Sumitomo Pharma America, Inc.10$208
Otsuka America Pharmaceutical, Inc.4$188
Exact Sciences8$178
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)2$178
Johnson & Johnson8$175
Insulet Corporation4$164
Corcept Therapeutics8$162
Phathom Pharmaceuticals, Inc.3$159
Biohaven Pharmaceuticals, Inc.2$143
Bard Peripheral Vascular, Inc.2$137
Alkermes, Inc.2$136
Sunovion Pharmaceuticals Inc.7$133
Takeda Pharmaceuticals U.S.A., Inc.13$129
Heartflow, Inc.1$117
Lifescan, Inc.6$113
Harmony Biosciences LLC3$105
Sanofi1$102
Kowa Pharmaceuticals America, Inc.5$101
Kestra Medical Technology Services, Inc.1$95
Inspire Medical Systems, Inc.1$91
Radius Health, Inc.4$87
Recordati_rare_diseases_inc.3$86
Xeris Pharmaceuticals, Inc.4$75
Bayer4$70
Regeneron Healthcare Solutions, Inc.4$69
Axsome Therapeutics, Inc.3$68
Sanofi Pasteur Inc.5$68
Amneal Pharmaceuticals LLC3$58
Brainsway USA Inc1$50
IBSA Pharma Inc.3$48
Ultragenyx Pharmaceutical Inc.2$37
Cequr Corporation1$35
Aimmune Therapeutics, Inc.1$34
Dynavax Technologies Corporation2$28
Clarus Therapeutics Inc.2$28
Avadel CNS Pharmaceuticals, LLC1$28
KCI USA, Inc.1$26
Nevro Corp.1$24
Jazz Pharmaceuticals Inc.1$24
Tandem Diabetes Care, Inc.1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,735 in reported general payments places this provider in the 95th percentile of 477 internal medicine providers in Delaware.

See all internal medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$347,801
Medicare patients
688
Services billed
6,986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide129$188,090
EliquisApixaban185$183,118
JardianceEmpagliflozin95$134,960
RybelsusSemaglutide48$120,127
XareltoRivaroxaban36$48,458
GemtesaVibegron68$44,290
MyrbetriqMirabegron39$42,982
FarxigaDapagliflozin Propanediol26$41,681
JanuviaSitagliptin Phosphate24$38,896
Xultophy 100-3.6Insulin Degludec/Liraglutide11$29,554
JanumetSitagliptin Phos/Metformin Hcl16$22,517
NexletolBempedoic Acid19$21,995
Rosuvastatin Calcium768$20,783
SynthroidLevothyroxine Sodium388$20,150
TradjentaLinagliptin16$18,228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6$2,530$337,771188 claims
PfizerEliquis$591$183,118185 claims
Boehringer IngelheimJardiance, Tradjenta$1,059$153,188111 claims
MerckJanuvia, Janumet$244$61,41440 claims
Johnson & JohnsonXarelto$175$48,45836 claims
AstraZenecaFarxiga, Breztri Aerosphere$2,564$48,36137 claims
Sumitomo Pharma America, Inc.Gemtesa$208$44,29068 claims
Astellas Pharma US IncMyrbetriq$468$42,98239 claims
Esperion Therapeutics, Inc.Nexletol$256$21,99519 claims
AbbVieSynthroid$1,218$20,150388 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$58$9,0751,024 claims
GSKBreo Ellipta$470$6,87012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 477 internal medicine providers in Delaware.

Other internal medicine in Lewes

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →